Alexander Kharchenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander Kharchenko has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alexey Valerievich Polonikov
Kursk State Medical University, Kursk, Russia
4 shared publications - Olga Yurievna Bushueva
Kursk State Medical University
3 shared publications - Vadim P. Mikhin
Kursk State Medical University
3 shared publications - Anna V. Bocharova
Research Institute of Medical Genetics, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
2 shared publications E. Yu. Klesova
Kursk state medical university Ministry of health of Russia
2 shared publications- Galina Sergeevna Mal’
Курский государственный медицинский университет
2 shared publications
Latest Publications
- Open Access
- 4 March 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (1) , 17-23-23
Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin
Полиморфные варианты гена аполипопротеина E: связь с риском развития ишемической болезни сердца и эффективностью гиполипидемической терапии розувастатином
- 4 March 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (1) , 17-23-23
Open AccessApolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin
Полиморфные варианты гена аполипопротеина E: связь с риском развития ишемической болезни сердца и эффективностью гиполипидемической терапии розувастатином
- Open Access
- 4 March 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (1) , 17-23
Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin
Полиморфные варианты гена аполипопротеина E: связь с риском развития ишемической болезни сердца и эффективностью гиполипидемической терапии розувастатином
- 4 March 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (1) , 17-23
Open AccessApolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin
Полиморфные варианты гена аполипопротеина E: связь с риском развития ишемической болезни сердца и эффективностью гиполипидемической терапии розувастатином
- Open Access
- 1 February 2018
- Published by Wiley in Disease Markers
- Vol. 2018, 1-12
A Novel Polymorphism in the Promoter of theCYP4A11Gene Is Associated with Susceptibility to Coronary Artery Disease
Enzymes CYP4A11 and CYP4F2 are involved in biosynthesis of vasoactive 20-hydroxyeicosatetraenoic acid and may contribute to pathogenesis of coronary artery disease (CAD). We investigated whether polymorphisms of theCYP4A11andCYP4F2genes are associated with the risk of CAD in Russian population. DNA samples from 1323 unrelated subjects (637 angiographically confirmed CAD patients and 686 age- and sex-matched healthy individuals) were genotyped for polymorphisms rs3890011, rs9332978, and rs9333029 ofCYP4A11and rs3093098 and rs1558139 ofCYP4F2by using the Mass-ARRAY 4 system. SNPs rs3890011 and rs9332978 ofCYP4A11were associated with increased risk of CAD in women: OR = 1.26, 95% CI: 1.02–1.57,, andand OR = 1.45, 95% CI: 1.13–1.87,, and, respectively. Haplotype G-C-A ofCYP4A11was associated with increased risk of CAD (adjusted OR = 1.41, 95% CI: 1.12–1.78, and). Epistatic interactions were found between rs9332978 ofCYP4A11and rs1558139 ofCYP4F2(). In silico analysis allowed identifying that SNP rs9332978 is located at a binding site for multiple transcription factors; many of them are known to regulate the pathways involved in the pathogenesis of CAD. This is the first study in Europeans that reported association between polymorphism rs9332978 ofCYP4A11and susceptibility to coronary artery disease.- 1 February 2018
- Published by Wiley in Disease Markers
- Vol. 2018, 1-12
Open AccessA Novel Polymorphism in the Promoter of theCYP4A11Gene Is Associated with Susceptibility to Coronary Artery Disease
Enzymes CYP4A11 and CYP4F2 are involved in biosynthesis of vasoactive 20-hydroxyeicosatetraenoic acid and may contribute to pathogenesis of coronary artery disease (CAD). We investigated whether polymorphisms of theCYP4A11andCYP4F2genes are associated with the risk of CAD in Russian population. DNA samples from 1323 unrelated subjects (637 angiographically confirmed CAD patients and 686 age- and sex-matched healthy individuals) were genotyped for polymorphisms rs3890011, rs9332978, and rs9333029 ofCYP4A11and rs3093098 and rs1558139 ofCYP4F2by using the Mass-ARRAY 4 system. SNPs rs3890011 and rs9332978 ofCYP4A11were associated with increased risk of CAD in women: OR = 1.26, 95% CI: 1.02–1.57,, andand OR = 1.45, 95% CI: 1.13–1.87,, and, respectively. Haplotype G-C-A ofCYP4A11was associated with increased risk of CAD (adjusted OR = 1.41, 95% CI: 1.12–1.78, and). Epistatic interactions were found between rs9332978 ofCYP4A11and rs1558139 ofCYP4F2(). In silico analysis allowed identifying that SNP rs9332978 is located at a binding site for multiple transcription factors; many of them are known to regulate the pathways involved in the pathogenesis of CAD. This is the first study in Europeans that reported association between polymorphism rs9332978 ofCYP4A11and susceptibility to coronary artery disease. - 17 November 2014
- Published by Bionika Media in Kardiologiia
- Vol. 11_2014 (11) , 11-9
Efficiency of Meldonium in the Complex Therapy of Acute Coronary Syndrome
We examined 140 patients (mean age 54.8±3.1 years) with ST elevation acute coronary syndrome resulting in Q-wave myocardial infarction of the left ventricle. From the first hours complex therapy of these patients comprised meldonium (1 g/day intravenously for 2 weeks then orally until 1.5 months). Therapy with meldonium accelerated restoration of left ventricular diastolic function what was in agreement with lowering of NT-proBNT concentration in blood. It was established that administration of meldonium led to reduction of number of high grade ventricular extrasystoles during first 6 hours after thrombolysis, to lowering of blood concentration of lipoperoxide degradation products. Early use of meldonium decreases probability of emergence of fatal arrhythmias and improves prognosis of hospital stage of rehabilitation of patients with acute coronary syndrome resulting in Q-wave myocardial infarction.
- 17 November 2014
- Published by Bionika Media in Kardiologiia
- Vol. 11_2014 (11) , 11-9
Efficiency of Meldonium in the Complex Therapy of Acute Coronary Syndrome
We examined 140 patients (mean age 54.8±3.1 years) with ST elevation acute coronary syndrome resulting in Q-wave myocardial infarction of the left ventricle. From the first hours complex therapy of these patients comprised meldonium (1 g/day intravenously for 2 weeks then orally until 1.5 months). Therapy with meldonium accelerated restoration of left ventricular diastolic function what was in agreement with lowering of NT-proBNT concentration in blood. It was established that administration of meldonium led to reduction of number of high grade ventricular extrasystoles during first 6 hours after thrombolysis, to lowering of blood concentration of lipoperoxide degradation products. Early use of meldonium decreases probability of emergence of fatal arrhythmias and improves prognosis of hospital stage of rehabilitation of patients with acute coronary syndrome resulting in Q-wave myocardial infarction.
- 1 January 2012
- Vol. 52 (10) , 4-8
[Efficacy of the use of coenzyme q10 at the background of traditional therapy of chronic ischemic heart disease].
- 1 January 2012
- Vol. 52 (10) , 4-8
[Efficacy of the use of coenzyme q10 at the background of traditional therapy of chronic ischemic heart disease].
- 1 January 2011
- Vol. 51 (6) , 26-31
[Application of coenzyme Q(10) in combination therapy of arterial hypertension].
We studied effect of coenzyme Q(10) on 24-hour blood pressure profile and function of vascular endothelium in patients with essential hypertension. Coenzyme Q(10) was used as a component of combination therapy comprising angiotensin converting enzyme inhibitor enalapril. Administration of coenzyme Q(10) in combination with traditional antihypertensive therapy promoted normalization of vascular endothelial function and more effective correction of 24-hour blood pressure profile. These findings allow to consider the use of coenzyme Q(10) as promising component of combination therapy of arterial hypertension.
- 1 January 2011
- Vol. 51 (6) , 26-31
[Application of coenzyme Q(10) in combination therapy of arterial hypertension].
We studied effect of coenzyme Q(10) on 24-hour blood pressure profile and function of vascular endothelium in patients with essential hypertension. Coenzyme Q(10) was used as a component of combination therapy comprising angiotensin converting enzyme inhibitor enalapril. Administration of coenzyme Q(10) in combination with traditional antihypertensive therapy promoted normalization of vascular endothelial function and more effective correction of 24-hour blood pressure profile. These findings allow to consider the use of coenzyme Q(10) as promising component of combination therapy of arterial hypertension.